Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Consolidated Net Income (2016 - 2026)

PharmaCyte Biotech has reported Consolidated Net Income over the past 17 years, most recently at -$1.9 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 167.89% to -$1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Jan 2026, up 57.06% year-over-year, with the annual reading at $7.9 million for FY2025, 126.39% up from the prior year.
  • Consolidated Net Income was -$1.9 million for Q1 2026 at PharmaCyte Biotech, down from -$1.2 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $10.0 million in Q2 2025 and troughed at -$1.9 million in Q1 2026.
  • The 5-year median for Consolidated Net Income is -$810660.0 (2022), against an average of $52034.3.
  • Year-over-year, Consolidated Net Income soared 3521.74% in 2024 and then plummeted 167.89% in 2026.
  • A 5-year view of Consolidated Net Income shows it stood at -$1.9 million in 2022, then surged by 72.6% to -$515339.0 in 2023, then plummeted by 40.39% to -$723498.0 in 2024, then plummeted by 61.67% to -$1.2 million in 2025, then plummeted by 61.37% to -$1.9 million in 2026.
  • Per Business Quant, the three most recent readings for PMCB's Consolidated Net Income are -$1.9 million (Q1 2026), -$1.2 million (Q4 2025), and -$630512.0 (Q3 2025).